UK tirzepatide price rise shifted use

A retrospective study of 1,033,522 self-paying UK adults found a sharp shift from tirzepatide toward semaglutide around a September 2025 tirzepatide list-price increase of up to 170%. Semaglutide initiation rose by 31.15 percentage points relative to the projected prior trend, while switching from tirzepatide to semaglutide rose by 9.26 points before later easing^[1].

The price change created a natural break

Dix and colleagues studied adults who started semaglutide or tirzepatide through MedExpress from 1 May 2024 to 1 January 2026. They used a segmented interrupted time-series model to compare treatment patterns around the September 2025 price increase with the trend projected from the earlier period. A sensitivity analysis tested whether behavior began changing in August, before the formal interruption. Weight trajectories were estimated separately with linear mixed-effects models^[2].

An interrupted time series can detect whether a level or trend changes around a dated event. It does not randomize people to face different prices. Other events occurring at the same time could influence prescribing, availability or patient choice. The study's sensitivity analyses support anticipatory movement in August, which fits awareness before the increase, but the abstract does not list every competing market or provider change that the model considered.

Initiation and switching moved toward semaglutide

Most people in the full cohort began tirzepatide. Of 1,033,522 adults, 932,659, or 90.2%, initiated tirzepatide and 100,863, or 9.8%, initiated semaglutide. In September 2025, semaglutide initiation increased by 31.15 percentage points relative to the projected pre-interruption trend. The 95% confidence interval ran from 26.07 to 36.24 points^[1].

Switching from tirzepatide to semaglutide rose by 9.26 percentage points, with a 95% confidence interval from 7.09 to 11.42. That increase later attenuated. The analysis also found signs that behavior changed in August, before the September date^[2]. Together, those patterns are consistent with price-sensitive treatment selection in a self-funded service. They do not show what any individual paid or prove that price was the only reason for every switch.

Twelve-month weight estimates need context

The model estimated 12-month weight loss of 19.93% with tirzepatide and 16.40% with semaglutide among patients who contributed follow-up measurements. Data for the tirzepatide estimate came from 30,763 people, while the semaglutide estimate used 979. Reported 95% confidence intervals were 19.88% to 19.98% and 16.16% to 16.64%, respectively^[1].

Those figures are not a randomized head-to-head comparison. Treatment choice could be related to price, patient characteristics, clinician decisions, prior response or the calendar period in which someone entered care. Follow-up contributors are also a small subset of the million-person initiation cohort, especially for semaglutide. The abstract does not provide a direct adjusted contrast between medicines or explain in detail why some patients had 12-month weights while most did not. Reading 19.93% versus 16.40% as proof of superiority would go beyond the reported design.

The cohort describes one commercial pathway

The sample came from one large UK telehealth provider and only included self-paying adults. That setting is central to the study question because relative price can affect a treatment decision directly. It also narrows how broadly the result applies. NHS pathways, other private providers and patients who stop seeking treatment when prices rise may show different patterns. Provider reach was higher among women than men, according to the abstract, but no detailed demographic distribution is available in the indexed summary.

Two authors were affiliated with HeliosX, the London company named in the PubMed author information, and the other authors were affiliated with Health Analytics at Lane Clark & Peacock. The cohort came through MedExpress. The indexed record does not include a conflict-of-interest statement or funding declaration at this stage. That absence should not be treated as proof that no commercial relationship exists; full-text disclosures should be checked when the final article becomes available.

What the study can support

The study supports a bounded market-behavior conclusion: initiation and switching patterns changed markedly around a large tirzepatide price increase in this self-funded telehealth cohort. Its scale makes the shift hard to dismiss as a handful of unusual decisions. The interrupted design and anticipatory analysis strengthen the timing argument. Even so, observational timing cannot establish that price alone caused each choice, and the study does not evaluate clinical outcomes from switching as a randomized strategy.

The weight analysis shows substantial estimated loss among patients who remained observable at 12 months, in a service the authors describe as offering limited adjunctive lifestyle support. It does not provide a personal forecast, a reason to switch medicines or a protocol for doing so. Treatment continuity, side effects and medical history all matter, while sudden changes can carry clinical and access consequences. Decisions about either prescription medicine belong with a qualified healthcare professional.

What to watch after this readout

Full publication should clarify baseline differences between treatment groups, missing-weight handling, discontinuation and the disclosures attached to this commercial dataset. Longer follow-up could show whether the initial switching spike persisted, reversed or translated into different treatment continuity. Research across several providers and NHS settings would also show whether this was a broad UK response or a pattern specific to one self-paying service. For now, the strongest result concerns price-sensitive selection, not a controlled clinical comparison.